A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment can be reversed.
Not only were improvements sustained, but some patients returned to work, regained their ability to speak different languages, and showed an increase in brain matter volume after just a few months.
“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” says one of the team, Dale Bredesen, University of California, Los Angeles. “Follow up testing showed some of the patients going from abnormal to normal.”
The study investigated the effects of a new kind of personalised treatment on the cognitive abilities of 10 patients who were experiencing age-related decline.
The treatment – called metabolic enhancement for neurodegeneration, or MEND – is based on 36 different factors, including changes in diet, exercise, and sleeping habits, plus the integration of certain drugs, vitamins, and brain stimulation therapy to their regular routine.
These lifestyle changes and treatments were sustained for five to 24 months, and the team from UCLA and the Buck Institute for Research on Ageing in California reports that many of the patients showed real, life-altering improvements as a result.
According to the researchers, this is the first study to objectively show that memory loss in patients can be reversed, and improvement sustained.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” says Bredesen.
Publishing their results in the journal Aging, the team hasn’t gone into much detail about how MEND works, probably because each treatment involves a complex combination of factors that has been specifically designed to treat just one individual, as each person’s version of Alzheimer’s appears to be different.
But they do mention something that all but one of the patients have in common – they are all at genetic risk for Alzheimer’s disease, carrying at least one copy of the APOE4 allele. Five of the patients are carrying two copies of APOE4, which gives them a 10- to 12-fold increased risk of developing the disease, the team explains.
This means there could be some benefit in getting tested for this genetic risk, because patients might finally be able to do something to stall the progression of the disease. Around 65 percent of Alzheimer’s cases in the US involve APOE4.
“We’re entering a new era,” says Bredesen. “The old advice was to avoid testing for APOE because there was nothing that could be done about it. Now we’re recommending that people find out their genetic status as early as possible so they can go on prevention.”
The Latest on: APOE4
via Google News
The Latest on: APOE4
- Researchers Discover Why ApoE4 Increases the Risk of Alzheimer’s Diseaseon June 26, 2020 at 5:00 am
Researchers from the Max Delbrück Center for Molecular Medicine may have found an explanation as to why ApoE4 increases the risk of Alzheimer's disease.
- How ApoE4 endangers the brainon June 26, 2020 at 4:19 am
But not all ApoE is the same. There are three gene variants in humans: ApoE2, ApoE3 and ApoE4. They do not differ in their function of transporting lipids. The ability to bind to sortilin is also ...
- Study shows why ApoE4 increases risk of Alzheimer's diseaseon June 26, 2020 at 12:10 am
Apolipoprotein E (ApoE) is kind of like a delivery service for the human brain. It supplies neurons with important nutrients, including with polyunsaturated fatty acids - which are building blocks of ...
- New brain alterations induced by main genetic risk factor in Alzheimer's disease discoveredon June 23, 2020 at 5:28 am
A study led by the Institut de Neurociències (INc-UAB) shows that APOE4, the principal genetic risk factor for the most common type of Alzheimer's disease, produces an alteration in the astrocytes' ...
- Study finds path for addressing Alzheimer’s blood-brain barrier impairmenton June 15, 2020 at 11:44 am
By developing a lab-engineered model of the human blood-brain barrier (BBB), neuroscientists at MIT’s Picower Institute for Learning and Memory have discovered how the most common Alzheimer’s disease ...
- Human Blood-Brain Barrier Model Blames Pericytes for CAAon June 15, 2020 at 8:45 am
Blood-brain barrier model combines human astrocytes, pericytes, and endothelial cells. APOE4 in pericytes, but not the other cells, promoted cerebral amyloid angiopathy. Blocking NFAT signaling ...
- Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericyteson June 8, 2020 at 8:04 am
Apolipoprotein (APOE4) is the strongest risk factor for CAA, yet the mechanisms underlying this genetic susceptibility are unknown. Here we developed an induced pluripotent stem cell-based three ...
- Study finds path for addressing Alzheimer's blood-brain barrier impairmenton June 8, 2020 at 8:02 am
About 25 percent of people have the APOE4 variant of the APOE gene, which puts them at substantially greater risk for Alzheimer's disease. Almost everyone with Alzheimer's, and even some elderly ...
- Faulty gene linked to dementia ‘doubles the risk of severe Covid-19’on June 5, 2020 at 12:42 am
Scientists have said a faulty gene called ApoE4, found in people of European ancestry, is linked to a greater risk of severe Covid-19, even when they were not affected by dementia. They said their ...
- Faulty ApoE4 gene increases risk for Alzheimer’s and for COVID-19on May 27, 2020 at 8:11 pm
The faulty gene, called ApoE4, usually found in people of European ancestry, is tied to a heightened risk of severe COVID-19, even when they were not affected by dementia. The scientists suggest ...
via Bing News